glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	Weight gain	1610	1746	Weight gain was low (<1 kg) in both groups, with less gain with Gla-300 [LS mean difference −0.28 kg (95% CI −0.55 to −0.01); p = 0.039]
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	mean decrease in HbA1c level	16281	16589	the mean decrease in HbA1c level was similar in the two treatment groups (Figure 1A). The least squares (LS) mean [standard error (s.e.)] change in HbA1c from baseline to month 6 was comparable for Gla-300 and Gla-100 [each −1.02 (0.03)%; LS mean difference 0.00, 95% confidence interval (CI) −0.08 to 0.07%]
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	Weight gain	1610	1747	Weight gain was low (<1 kg) in both groups, with less gain with Gla-300 [LS mean difference −0.28 kg (95% CI −0.55 to −0.01); p = 0.039].
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	Average pre-injection self-monitored plasma glucose (SMPG) decrease	17065	17325	Average pre-injection SMPG also decreased in both treatment groups, and reductions from baseline to month 6 were similar for Gla-300 and Gla-100 [LS mean (s.e.) change −1.43 (0.08) and −1.34 (0.08) mmol/l; LS mean difference −0.09, 95% CI −0.31 to 0.14 mmol/l]
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	participants who reached target HbA1c after 6 months of treatment	16609	16823	participants who reached target HbA1c after 6 months of treatment was similar in both treatment groups; 449 participants (36.2%) on Gla-300 and 438 participants (35.5%) on Gla-100 attained an HbA1c target of <7.0%.
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	Average pre-injection self-monitored plasma glucose (SMPG) decrease	17065	17209	Average pre-injection SMPG also decreased in both treatment groups, and reductions from baseline to month 6 were similar for Gla-300 and Gla-100
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	mean decrease in HbA1c level	16238	16366	n the pooled dataset of all three studies, the mean decrease in HbA1c level was similar in the two treatment groups (Figure 1A).
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	annualized rate (events per participant-year) of confirmed [≤3.9 mmol/l (≤70 mg/dl)] or severe hypoglycaemia at any time of day (24 h) over the 6-month	1222	1433	Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with Gla-300 than with Gla-100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference).
glargine 300 U/ml (Gla-300)	glargine 100 U/ml (Gla-100)	participants who reached target HbA1c after 6 months of treatment	16591	16823	The proportion of participants who reached target HbA1c after 6 months of treatment was similar in both treatment groups; 449 participants (36.2%) on Gla-300 and 438 participants (35.5%) on Gla-100 attained an HbA1c target of <7.0%.
